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I M M U N O L O G Y
Macrophage miR-210 induction and metabolic 
reprogramming in response to pathogen interaction 
boost life-threatening inflammation
Federico Virga1,2,3,4, Federica Cappellesso1,2, Benoit Stijlemans5,6, Anne-Theres Henze1,2, 
Rosa Trotta1,2, Jonas Van Audenaerde7, Ananda S. Mirchandani8, Manuel A. Sanchez-Garcia8, 
Jolien Vandewalle9, Francesca Orso3,4, Carla Riera-Domingo1,2, Alberto Griffa3,4, 
Cristina Ivan10,11, Evelien Smits7, Damya Laoui5,6, Fabio Martelli12, Lies Langouche13, 
Greet Van den Berghe13, Olivier Feron14, Bart Ghesquière15,16, Hans Prenen7,17, Claude Libert9, 
Sarah R. Walmsley8, Cyril Corbet14, Jo A. Van Ginderachter5,6, Mircea Ivan18,  
Daniela Taverna3,4†, Massimiliano Mazzone1,2,3,4*†
Unbalanced immune responses to pathogens can be life-threatening although the underlying regulatory mecha-
nisms remain unknown. Here, we show a hypoxia-inducible factor 1–dependent microRNA (miR)–210 up-regulation 
in monocytes and macrophages upon pathogen interaction. MiR-210 knockout in the hematopoietic lineage or in 
monocytes/macrophages mitigated the symptoms of endotoxemia, bacteremia, sepsis, and parasitosis, limiting 
the cytokine storm, organ damage/dysfunction, pathogen spreading, and lethality. Similarly, pharmacologic 
miR-210 inhibition improved the survival of septic mice. Mechanistically, miR-210 induction in activated macro-
phages supported a switch toward a proinflammatory state by lessening mitochondria respiration in favor of 
glycolysis, partly achieved by downmodulating the iron-sulfur cluster assembly enzyme ISCU. In humans, aug-
mented miR-210 levels in circulating monocytes correlated with the incidence of sepsis, while serum levels of 
monocyte/macrophage-derived miR-210 were associated with sepsis mortality. Together, our data identify miR-210 
as a fine-tuning regulator of macrophage metabolism and inflammatory responses, suggesting miR-210–based 
therapeutic and diagnostic strategies.
INTRODUCTION
The inflammatory response to the entry of pathogens is a complex 
and multistep process that needs to be tightly regulated since a trade- 
off between removal of the harmful stimulus and self-preservation 
must be established to return to tissue homeostasis (1). Notably, an 
unbalanced host immune response to infections can also culminate 
in sepsis, a deadly, life-threatening pathological syndrome (2) that 
can also be secondary to other diseases such as cancer (3).
Innate immune cells, most importantly macrophages, initiate a 
type 1 inflammatory response to infections by sensing the presence 
of invading pathogens (namely, bacteria, viruses, and parasites) via 
pattern recognition receptors, that recognize pathogen-associated 
molecular patterns such as lipopolysaccharide (LPS) (4). Following 
their recognition, monocytes extravasate and differentiate into mac-
rophages, starting to produce effector molecules including chemokines 
and cytokines [e.g., interferon- (IFN-), interleukin-6 (IL-6), IL-1, 
and tumor necrosis factor– (TNF-)] that activate other immune 
cell populations and endothelial cells (1). To fuel the higher biomass 
and the increased energy demands as well as to produce anti- or 
proinflammatory metabolites (e.g., itaconate or succinate, respec-
tively), activated immune cells rewire their metabolism (5, 6). For 
example, it is known that LPS-stimulated macrophages increase 
tremendously their glucose consumption rate at the expense of oxi-
dative metabolism (7). However, the molecular mechanisms under-
lying this functional switch are not yet completely unraveled, and it 
remains an open question whether metabolic changes occurring 
upon macrophage activation are epistatic to their phenotypic rewir-
ing. These are important issues since deciphering these processes 
might pave the way toward the development of new therapeutic 
strategies.
MicroRNAs (miRs) are small, single-stranded noncoding RNA 
molecules that mediate posttranscriptional repression by targeting 
specific mRNAs in a sequence-dependent manner (8). MiRs, for in-
stance, miR-155 and miR-146a, have been well recognized for their 
important contribution to inflammatory responses (9). However, 
miRs are only recently emerging as mediators of metabolic rewiring 
in immune cells (8, 10).
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Here, we characterize miR-210, classically studied in conditions 
of low oxygen tension such as cancer and ischemia (11, 12) and for 
this reason renamed hypoxia-miR (13, 14) as an important executor 
of the switch to classical (M1) activation and, consequently, of the 
inflammatory responses in macrophages. Several metabolic targets 
such as the integral components of the ETC (electron transport 
chain) NDUFA4 (15), succinate dehydrogenase complex subunit D 
(15), cytochrome c oxidase 10 (16), and proteins involved in the 
synthesis and maturation of cofactors essential for the ETC such 
as ISCU (iron-sulfur cluster assembly enzyme) (16, 17) have been 
identified mostly in cancer cells. In contrast, although an in vitro 
study argues in favor of miR-210 as a potential negative regulator of 
proinflammatory cytokines (18), there are no data investigating its 
involvement in the metabolic rewiring of macrophages, how this is 
linked to their phenotypic switch, and how the entire cascade is 
relevant for disease outcome. By using genetic and pharmacologic 
approaches to target miR-210 in mice, we show the metabolic and 
immunological implications of miR-210 in macrophages in the 
context of several infectious/inflammatory disease models. More-
over, we provide a proof of evidence that miR-210 might be a 
suitable target for the treatment and management of these diseases. 
Last, we tentatively transfer this knowledge to the human setting by 
studying miR-210 in cultured human macrophages and correlating 
miR-210 levels in circulating monocytes and serum of patients 
with sepsis.
RESULTS
MiR-210 deletion in the hematopoietic lineage confers 
protection against sepsis and parasitic infections
We started by assessing the functional relevance of miR-210 expres-
sion in the immune system in vivo during various inflammatory/
infectious events. For this purpose, we reconstituted lethally irra-
diated C57BL/6 wild-type (WT) recipient mice with bone marrow 
cells derived from either miR-210 WT or knockout (KO) donors. 
Both reconstituted WT and KO chimeras (WT➔WT and miR-210 
KO➔WT, respectively) displayed normal blood counts when com-
pared to control mice (table S1).
We then applied a single-shot intraperitoneal LPS injection 
mimicking an endotoxin-septic shock. Here, we found that loss of 
miR-210 expression in the hematopoietic lineage was protective 
against LPS-induced endotoxemia and substantially enhanced the 
survival of miR-210 KO chimeras (Fig. 1A). A less severe response 
to this systemic inflammation was further supported by a milder 
drop in body temperature (Fig. 1B).
Mortality in LPS-induced endotoxemia is generally due to the 
overwhelming inflammatory response that leads to a progressive 
organ damage, ultimately resulting in organ dysfunction. Following 
LPS challenge, livers from miR-210 KO chimeras exhibited fewer 
apoptotic hepatocytes compared to controls, as assessed by TUNEL 
(terminal deoxynucleotidyl transferase–mediated deoxyuridine tri-
phosphate nick end labeling) staining on liver sections (Fig. 1, 
C and D). Similarly, the histological analysis of kidneys revealed a 
reduced glycogen deposition after LPS challenge in KO chimeras 
pointing to milder renal damage in LPS-challenged miR-210 KO 
chimeras (Fig. 1, E and F). In line with these results, we also ob-
served reduced lactate dehydrogenase (LDH) and creatinine plasma 
levels in miR-210 KO mice indicating a better preservation of liver 
and kidney functionality, respectively (Fig. 1, G and H).
To evaluate the role of miR-210  in a more clinically relevant 
model, we adopted the cecal ligation and puncture (CLP) protocol 
as an experimental model for polymicrobial sepsis (19). Consistently, 
also in this model, we observed an increased survival of KO versus 
WT chimeras, associated with a milder drop in body temperature, 
further supporting the protective function against septic shock con-
ferred by hematopoietic miR-210 depletion (Fig. 1, I and J).
Both LPS-induced endotoxemia and CLP models are fast and 
acute disease models. We aimed to understand whether miR-210 
deficiency could affect the progression and/or outcome of a disease 
that leads to a chronic state. In addition, we questioned whether 
miR-210 could be involved in parasite-mediated infectious diseases 
and not only during the course of bacterial infections. Therefore, we 
opted for a parasite disease model and specifically for an infection 
with Trypanosoma brucei, an extracellular protozoan that, in hu-
mans, leads to African trypanosomiasis (HAT), better known as 
sleeping sickness (20). To evaluate the functional role of miR-210 in 
this model, we intraperitoneally injected the T. brucei AnTat1.1E 
strain in WT and miR-210 KO chimeras and we followed the sur-
vival as well as the main clinical disease symptoms (20). Although 
miR-210 KO chimeras displayed only mild differences in parasitemia 
levels during T. brucei infection at days 5 and 20 (fig. S1A), miR-210 
ablation in the hematopoietic lineage conferred disease protection 
and increased survival (Fig. 1K). This disease protection consisted 
in a milder body weight loss as well as a less severe anemia during 
the chronic stage of the disease (Fig. 1L and fig. S1B), two critical 
immunopathological features associated with HAT. Overall, these 
data demonstrate that miR-210 deletion in the immune system is 
able to protect the organism against endotoxemia and parasitic infec-
tions, both characterized by a proinflammatory immune response.
MiR-210 is up-regulated in monocytes and macrophages 
in response to pathogens
To understand which immune cell type was mostly involved in our 
phenotype, we analyzed miR-210 expression levels among different 
immune cell populations (B cells, T cells, neutrophils, and macro-
phages) isolated from peritoneal lavages at baseline and after LPS 
administration. Notably, macrophages were among the immune cells 
with the highest miR-210 levels at baseline and the only cell type that 
showed an induction upon LPS challenge (Fig. 2A). At baseline, the 
number of neutrophils was too low to reliably assess miR-210 levels 
(Fig. 2A). The representation of different immune cell populations 
in the peritoneal fluid from chimeric WT versus miR-210 KO mice 
before or after LPS challenge did not change (fig. S2, A and B). Consis-
tently, circulating monocytes in the blood displayed both the highest 
basal levels and the strongest up-regulation of miR-210 in response to a 
challenge with LPS (Fig. 2B). We further confirmed the up-regulation 
of miR-210 in macrophages and circulating monocytes isolated, upon 
in vivo exposure to LPS, either by selective adhesion of peritoneal 
macrophages to nontreated culture dishes or by CD115+ magnetic 
beads, respectively (fig. S2, C and D). All these expression data suggest 
a possible role of miR-210 in monocyte/macrophage responses during 
LPS-induced endotoxemia.
To better investigate miR-210 regulation in macrophages, we 
moved to an in vitro system. We found that miR-210 levels were 
up-regulated in bone marrow–derived macrophages (BMDMs) after 
stimulation with bacterial/proinflammatory (M1) stimuli, consist-
ing in the combination of LPS and IFN- but not in response to LPS or 
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stimuli such as IL-4 did not significantly affect miR-210 levels 
(Fig. 2C). A similar induction of miR-210 expression was observed 
in peritoneal macrophages in response to LPS/IFN-, but not after 
exposure to anti-inflammatory cytokines such as IL-4 or IL-13 
(fig. S2F). Although the increased miR-210 levels by the combina-
tion of LPS/IFN- stimulation may seem to contradict the in vivo 
evidence showing miR-210 induction by LPS alone, it is well 
documented that IFN- is acutely released by the host upon LPS 
challenge (21).
The miR-210 gene locus is characterized by a hypoxia-response 
element, a promoter region recognized and bound by the transcrip-
tion factor hypoxia-inducible factor 1 (HIF-1), and consequently, 
HIF-1 works as a paramount miR-210 regulator (13, 14). Despite 
the name, HIF-1 can be regulated by many other factors besides 
Fig. 1. MiR-210 deletion in the hematopoietic lineage increases survival and mitigates the symptoms of inflammatory diseases. (A and B) Survival (A) and delta 
body temperature (°C) (B) of WT➔WT (n = 7) and miR-210 KO➔WT (n = 10) mice injected intraperitoneally with LPS. (C and D) Quantification (C) and representative imag-
es (D) of liver apoptosis assessed by TUNEL staining of WT➔WT and miR-210 KO➔WT (PBS = 3 and 3; LPS = 4 and 4). (E and F) Quantification (E) and representative imag-
es (F) of glycogen-positive areas in kidneys on periodic acid–Schiff (PAS)–stained kidney sections from WT➔WT and miR-210 KO➔WT mice (PBS = 3 and 3; LPS = 7 and 7). 
Arrows indicate PAS-positive areas of renal tubules. (G and H) Concentration of plasma LDH (PBS = 3 and 3; LPS = 7 and 8) and creatinine (PBS = 3 and 3; LPS = 7 and 6) in 
WT➔WT and miR-210 KO➔WT mice. (I) Survival of WT➔WT (n = 30) and miR-210 KO➔WT (n = 29) mice subjected to CLP. (J) Representative body temperature (°C) of 
WT➔WT (n = 20) and miR-210 KO➔WT (n = 20) mice subjected to CLP. (K) Survival of WT➔WT (n = 11) and miR-210 KO➔WT (n = 11) mice infected with Trypanosoma 
brucei parasites. (L) Body weight loss (% versus pre-infection) of WT➔WT (n = 16) and miR-210 KO➔WT (n = 15) mice infected with T. brucei parasite. Temperature, histol-
ogy, and plasma analysis (B to H) were assessed 18 hours after LPS injection. Data show a representative of two (A, B, and K) or a pool of three (I) or two (J) independent 
experiments. P value was assessed by Log-rank (Mantel-Cox) test (A, I, and K); two-tailed, unpaired, Student’s t test (B); and two-way analysis of variance (ANOVA) with 
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Fig. 2. MiR-210 is up-regulated both in vivo and in vitro in response to pathogens. (A and B) MiR-210 levels [quantitative real-time PCR (qRT-PCR)] in CD45+ sorted 
peritoneal (A) and circulating blood cells (B) 18 hours after intraperitoneal injection of LPS or phosphate-buffered saline (PBS): T cells (TCR +), B cells (B220+), neutrophils 
(F4/80−, Ly6G+), macrophages (Ly6G−, F4/80+), or monocytes (Ly6G−, CD115+). (C and D) MiR-210 levels (qRT-PCR) (C) and hypoxia-inducible factor 1 (HIF-1) protein 
(Western blot) (D) in bone marrow–derived macrophages (BMDMs), untreated or after LPS/IFN- or IL-4 stimulation. The percentage attached to the blot indicates densito-
metric changes. (E) MiR-210 levels (qRT-PCR) in BMDMs untreated or after 24-hour LPS/IFN- stimulation. BMDMs were electroporated 24 hours before LPS/IFN- treatment 
with small interfering RNAs (siRNAs) against HIF-1 or a control sequence. (F to K) MiR-210 levels (qRT-PCR) (F to H) and HIF-1 protein (Western blot) (I to K) in BMDMs 
cocultured with either heat-killed Pseudomonas aeruginosa (F and I) or heat-killed Streptococcus pneumoniae (G and J) or stimulated with lysate from T. brucei (H and K). 
The percentage attached to the blot indicates densitometric changes. (L to N) MiR-210 (L), HIF1A (M), and IL6 (N) mRNA levels (qRT-PCR) in human monocyte-derived 
macrophages (hMDMs) untreated or exposed for 12 hours to the SARS-CoV-2 spike protein. For all the in vitro analyses, unless specified in the legend (E and L to N), the 
treatment (C, D, F to K) was 44 hours. Data show a pool (A, C, and L to N) or a representative (B) of two independent experiments. P value was assessed by multiple Stu-
dent’s t test (A); two-way ANOVA with Sidak’s (B) and Tukey’s (E) multiple comparisons test; one-way ANOVA with Dunnett’s multiple comparison test (C); and two-tailed, 
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low oxygen tension such as inflammatory stimuli (22). Consistent 
with the literature and with the expression pattern of miR-210 
(23, 24), we found that HIF-1 was synergistically stabilized by the 
combination of LPS and IFN-, but much less by each of them alone 
and not at all by IL-4 (Fig. 2D and fig. S2G). In support of the in-
volvement of HIF-1 in the induction of miR-210, silencing of HIF-1 
by small interfering RNAs (siRNAs) abolished miR-210 up-regulation 
in BMDMs upon LPS/IFN- stimulation (Fig. 2E and fig. S2H).
MiR-210 was up-regulated in BMDMs not only by the Gram- 
negative bacteria component LPS but also by exposure to heat- 
inactivated Gram-negative bacteria, such as Pseudomonas aeruginosa, 
heat-killed Gram-positive Streptococcus pneumoniae [leading cause 
of human sepsis (25)], and T. brucei lysates (Fig. 2, F to H). All of 
these pathogenic stimuli promoted HIF-1 accumulation as well 
(Fig. 2, I to K). Recent findings show that HIF-1 is also stabilized 
in monocytes in response to severe acute respiratory syndrome coro-
navirus 2 (SARS-CoV-2) infection (26). We found that in vitro culture 
of human monocyte-derived macrophages (hMDMs) exposed to the 
spike protein of SARS-CoV-2, together with increasing transcript 
levels of HIF1A, up-regulates miR-210 and proinflammatory but not 
anti-inflammatory cytokines (Fig. 2, L to N, and fig. S2I). Therefore, 
miR-210 is specifically induced in monocytes and macrophages upon 
their interaction with (components of) both Gram-positive and 
Gram-negative bacteria, T. brucei, and SARS-CoV-2, most likely in 
an HIF-1–dependent manner.
Macrophage-specific or systemic targeting of miR-210 is 
sufficient to protect mice from endotoxic shock and infections
On the basis of our in vivo and in vitro findings, showing that miR-
210 expression is strongly regulated in macrophages upon pathogen 
interaction, we reasoned to specifically delete miR-210 expression in 
macrophages in vivo to evaluate the functional role of miR-210 in these 
cells. To this aim, we crossed miR-210 floxed mice with an inducible, 
macrophage-specific CSF1R:Cre-ERT (iCre) obtaining miR-210 M0 
(iCre-positive mice) mice and controls (iCre-negative mice)—a 
strategy that, in comparison to the bone marrow chimera approach, 
circumvents possible procedural side effects. Tamoxifen adminis-
tration effectively resulted in locus recombination (Fig. 3A). Then, 
Fig. 3. Inducible deletion in macrophages or systemic pharmacologic inhibition of miR-210 offers a therapeutic advantage in response to pathogens. (A) MiR-
210 levels (qRT-PCR) in sorted peritoneal macrophages (CD45+, Ly6G−, and F4/80+) from control (n = 4) and miR-210 M0 (n = 3) mice 5 days after tamoxifen administra-
tion. (B) Survival of control (n = 6) and miR-210 M0 (n = 7) mice injected intraperitoneally with LPS. (C) Body temperature in control (n = 8) and miR-210 M0 (n = 9) mice 
at baseline (T0) and 20 hours after S. pneumoniae infection (T20). (D) Viable bacterial counts recovered from homogenized lung (left) or whole blood (right) quantified as 
CFU from control (n = 8) and miR-210 M0 (n = 9) mice 20 hours after S. pneumoniae infection. (E) MiR-210 levels (qRT-PCR) in sorted peritoneal macrophages (CD45+, 
Ly6G−, and F4/80+) after 62 hours of a single intravenous administration of scramble (n = 4) or anti-miR-210 LNA (n = 4). (F) Survival of C57BL/6 mice injected intravenous-
ly with scramble LNA (n = 11) or anti-miR-210 LNA (n = 13) 48 hours before intraperitoneal LPS injection. Data show a representative (B) or a pool (C, D, and F) of two inde-
pendent experiments. P value was assessed by two-tailed, unpaired, Student’s t test (A and E); Log-rank (Mantel-Cox) test (B and F); two-way RM ANOVA with Sidak’s 









Virga et al., Sci. Adv. 2021; 7 : eabf0466     7 May 2021
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
6 of 18
we challenged these mice with a one-shot peritoneal LPS injection. 
Loss of miR-210 selectively in macrophages was sufficient to protect 
mice from the septic shock induced by the Gram-negative component 
LPS (Fig. 3B). Then, we tested the in vivo relevance of miR-210 
during Gram-positive infection of S. pneumoniae. As a systemic 
readout of inflammation, we measured the body temperature before 
and after intratracheal injection of a high dose of S. pneumoniae, 
which substantially dropped in control but not in miR-210 M0 
mice (Fig. 3C). Compared to controls, miR-210 M0 mice showed 
reduced counts of bacterial CFUs (i.e., colony-forming units) in the 
lung and in the blood (Fig. 3D). These data suggest that miR-210 
depletion in macrophages prevents the deleterious effects of a septic 
shock and, at the same time, it retains improved pathogen control.
From a therapeutic point of view, a macrophage-specific ap-
proach is very challenging. However, noncoding RNAs can be 
blocked by the systemic delivery of complementary antisense se-
quences of locked nucleic acids (LNAs), which are modified RNA 
structures with increased stability against enzymatic degradation (27). 
Therefore, we tested the effectiveness of LNA-mediated miR-210 
inhibition in the LPS-induced endotoxemia model. Down-regulation 
of miR-210 by the LNA was confirmed with quantitative real-time 
PCR (qRT-PCR) on sorted peritoneal macrophages (Fig. 3E). 
Systemic inhibition of miR-210, obtained by intravenous injection 
of the LNAs in C57BL/6 WT mice 48 hours before LPS challenge, 
resulted into a much longer survival compared to control mice that 
were treated with a scrambled LNA sequence (Fig. 3F). These data 
pave the way toward miR-210–based targeting approaches for the 
management of sepsis and other infectious diseases.
MiR-210 orchestrates the glycolytic switch of M1 macrophages
While both anti-inflammatory (M2-polarized) and resting/nonactivated 
(M0) macrophages rely more on oxidative phosphorylation (OXPHOS), 
proinflammatory (M1) macrophages respond to external stimuli such 
as LPS by increasing glycolysis at the expense of OXPHOS (6, 7, 28). 
However, it is not well known how the latter modulation is con-
trolled. When stimulated with LPS/IFN-, WT BMDMs increased 
glucose utilization as highlighted by a strong augmentation in gly-
colysis (Fig. 4, A to C). Yet, the increase in glycolysis upon treatment 
was significantly milder in miR-210 KO macrophages as assessed 
both by radioactive assays and by mass spectrometry (MS) analysis of 
intracellular and extracellular lactate accumulation (Fig. 4, A to C). 
No difference was observed in the untreated condition (Fig. 4, A to C).
When analyzing the fractional contribution of U-13C-glucose to the 
intermediates of the tricarboxylic acid (TCA) cycle (Fig. 4D), we 
noticed that 13C labeling of citrate, cis-aconitate, and itaconate, the 
latter an anti-inflammatory and antimicrobial metabolite (29), was 
higher in LPS/INF-–stimulated miR-210 KO versus WT macrophages 
(Fig. 4, E to G). Instead, the fractional contribution of U-13C-glucose 
to fumarate and malate was dropping comparably in the two genotypes 
(Fig. 4, H and I), consistent with a broken TCA cycle in M1-like 
macrophages (7). All of these data argue in favor of enhanced glu-
cose utilization into itaconate production through decarboxylation 
of cis- aconitate. Abundance of itaconate in response to LPS/INF- 
stimulation was increased in WT BMDMs (30), and this increase was 
even stronger in the absence of miR-210 (Fig. 4J). MS analysis of cul-
ture supernatants from LPS/INF-–stimulated BMDMs revealed that 
itaconate was also secreted (Fig. 4K), as also shown before (31). In ac-
cordance to the increased production of itaconate, its secretion was 
also enhanced in miR-210 KO versus WT macrophages (Fig. 4K).
M1-activated macrophages display reduced OXPHOS (6, 7). 
Consistently, the basal respiration of BMDMs upon administration 
of LPS/IFN- was strongly reduced (Fig. 4L). However, in treated 
miR-210 KO macrophages, this drop was less severe (Fig. 4L). To 
better investigate the involvement of the different components of 
the ETC, we analyzed the oxygen consumption rate (OCR) specifi-
cally related to complex I (assessed as the basal OCR in medium 
containing pyruvate and malate), complex II (assessed by succinate- 
related OCR, complex II substrate, in the presence of rotenone, 
complex I inhibitor), and complex IV (assessed by TMPD and 
ascorbate-related OCR, artificial complex IV substrates, in the pres-
ence of the complex III inhibitor antimycin A) on permeabilized 
macrophages (Fig. 4, M to P). In this setting, untreated WT and 
miR-210 KO macrophages did not display any significant differ-
ence in any of the OCR parameters. However, following LPS/IFN- 
stimulation, the activity of complexes I, II, and IV was reduced 
in WT BMDMs but significantly less miR-210 KO macrophages 
(Fig. 4, M to P). As expected (32), LPS/IFN- treatment led to a 
drop of the energy charge (Fig. 4Q), reflected by a reduction in the 
overall balance of adenosine triphosphate (ATP) (Fig. 4R). Never-
theless, this drop was less pronounced in miR-210 KO versus WT 
macrophages supporting the increased engagement of the ETC at 
the expense of glycolysis. Overall, our data argue that miR-210 in-
duction by LPS/IFN- is relevant to partly turn off OXPHOS and 
oxidative metabolism in favor of a pro-glycolytic rewiring, typical 
of M1 macrophages.
The iron-sulfur (Fe-S) cluster scaffold protein ISCU was shown 
to be one of the miR-210 targets in cancer and endothelial cells 
(16, 33). ISCU is involved in both the synthesis and maturation of 
2Fe-2S and 4Fe-4S clusters (34). Notably, the ETC has 12 different 
Fe-S clusters that play an important role in the electron transfer. 
Therefore, we hypothesized that ISCU could be implicated in the 
orchestration of the metabolic regulations observed in miR-210 KO 
BMDMs. Western blot analysis detected increased ISCU protein 
levels in miR-210 KO versus WT macrophages (Fig. 5A, left). Ac-
cordingly, overexpression of miR-210 led to a reduction of the pro-
tein level (Fig. 5A, right). We then tested whether the differences in 
OXPHOS could be reverted by ISCU silencing. Macrophages were 
silenced by electroporation with either a siRNA control (siCTRL) or 
a mix of two siRNAs for ISCU. As expected, miR-210 KO macro-
phages treated with siCTRL displayed an increase in OCR levels for 
complexes I, II, and IV upon LPS/IFN- (Fig. 5, B to E). Silencing of 
ISCU equalized the OCR of complexes I, II, and IV in miR-210 WT 
and KO macrophages, diminishing the activity of these complexes 
down to the same levels in both genotypes (Fig. 5, B to E). More-
over, silencing of ISCU increased the glycolytic flux (measured as 
lactate release) in miR-210 KO macrophages, equalizing it to the 
WT levels (Fig. 5F). Together, these data suggest that the metabolic 
reprogramming of macrophages dictated by miR-210–mediated 
modulation of ISCU mitigates OXPHOS and, indirectly, favors the 
glycolytic switch observed in M1-polarized macrophages.
MiR-210 enhances M1 responses in macrophages
To evaluate the impact of miR-210 on the macrophage phenotype, 
we performed a genome-wide messenger RNA profiling of either 
WT or miR-210 KO BMDMs, either untreated or treated with LPS/
IFN-. In the untreated condition, we identified only 220 differen-
tially expressed genes between WT and miR-210 KO macrophages. 
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Fig. 4. MiR-210 deletion in macrophages reduces glycolysis while enhancing oxidative metabolism in response to LPS/IFN-. (A) Glycolysis (3H-Glucose) of WT and 
miR-210 KO BMDMs untreated or after 18-hour LPS/IFN- stimulation. (B and C) Intracellular (B) and extracellular (C) lactate (liquid chromatography–mass spectrometry, 
LC-MS) from WT and miR-210 KO BMDMs untreated or after 24-hour LPS/IFN-. (D) Scheme of the TCA cycle and itaconate production. (E to I) Fractional contribution 
(LC-MS) of U-13C-glucose into different TCA cycle intermediates and derivates: citrate (E), cis-aconitate (F), itaconate (G), fumarate (H), and malate (I) in WT and miR-210 
KO BMDMs, untreated or after 24-hour LPS/IFN-. (J and K) Intracellular (J) and extracellular (K) itaconate (LC-MS) from WT and miR-210 KO BMDMs untreated or after 
24-hour (J) or 48-hour LPS/IFN- (K). (L) Basal respiration (seahorse) of WT and miR-210 KO BMDMs, untreated or after 24-hour LPS/IFN-. (M to P) A representative oxygen 
consumption rate (OCR) curve (M) and activity of complex I (N), complex II (O), or complex IV (P) (seahorse) on permeabilized WT and miR-210 KO BMDMs untreated or 
after 42-hour LPS/IFN- in the presence of pyruvate (Pyr) and malate (Mal). Rotenone, succinate, antimycin A, or TMPD + ascorbate was injected at the indicated time 
point. Complex activities in (N) to (P) were calculated by OCR subtractions. (Q and R) Energy charge (Q) and adenosine triphosphate (ATP) levels (R) (LC-MS) of WT and 
miR-210 KO BMDMs untreated or after 24-hour LPS/IFN-. Data were normalized by protein content (A to C and J to R). Data show a pool of two (A, B, E to K, and M to R) 
or three (C) or a representative of two (L) independent experiments. P value was assessed by two-way ANOVA with Sidak’s multiple comparisons test (A to R). Statistical 









Virga et al., Sci. Adv. 2021; 7 : eabf0466     7 May 2021
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
8 of 18
LPS/IFN- treatment, of which 1301 were down-regulated and 1176 
were up-regulated in miR-210 KO macrophages compared to WT 
macrophages, suggesting an involvement of miR-210 in response to 
pathogenic stimuli rather than at baseline. Gene ontology analysis 
revealed that M1-related pathways were less activated in miR-210 KO 
versus WT macrophages as highlighted by their appearance in the list 
of the differentially down-regulated genes in the treated condition. 
Examples of these M1 pathways are the positive regulation of cytokine 
production, autophagy, cytokine-mediated signaling pathways, anti-
gen processing and presentation, or terms related to general cell acti-
vation such as regulation of immune effector processes and regulation 
of innate immune responses (Fig. 6A). Conversely, gene ontology 
analysis on the differentially up-regulated genes in the treated condi-
tion highlighted cellular respiration and sulfur compound biosynthetic 
processes among the top 10 enriched pathways in miR-210 KO versus 
WT BMDMs, supporting the relevance of miR-210 in orchestrating 
the metabolic reprogramming of macrophages (Fig. 6B).
When looking at differential responses to treatment via pro-
teomics, results were consistent: IFN-–mediated signaling path-
ways, cell activation, response to cytokines, and immune effector 
processes were less represented in treated versus untreated miR-210 
KO macrophages, compared to what was seen in WT BMDMs in 
response to LPS/IFN- (fig. S3A). The most up-regulated terms 
were instead related to protein localization, which might underline 
a trend toward an anti-inflammatory, M2 state, as further examined 
in the discussion (fig. S3B). Overall, these findings suggest that 
miR-210 induction by LPS/IFN- enables a skewing of macro-
phages toward a functional and metabolic, inflammatory (M1-like) 
phenotype that exacerbates their responses to pathogenic stimuli.
In line with the omics data, classical M1 features (7, 35), such as 
major histocompatibility complex class II (MHC-II) expression, in-
ducible nitric oxide synthase (iNOS), and IL-6 secretion (Fig.  6, 
C to E), were less promoted in miR-210 KO than in WT macro-
phages upon in vitro treatment with LPS/IFN-. ISCU silencing in-
creased IL-6 release by miR-210 KO macrophages to the same levels 
as in WT macrophages along with increased MHC-II expression in 
both WT and miR-210 KO macrophages (Fig. 6, F and G). These data 
underscore the idea that ISCU loss of function can revert, at least in 
part, the inflammatory response controlled by miR-210 induction.
In vivo flow cytrometry analysis and enzyme-linked immuno-
sorbent assay (ELISA) revealed, respectively, lower MHC-II ex-
pression in macrophages from both liver and spleen and reduced 
plasma levels of IL-6 and TNF- in LPS-treated macrophage-specific 
miR-210 KO versus control mice (at a time point when the disease 
state was similar as assessed by body temperature) (Fig. 6, H to J, 
and fig. S3C). As a further sign of reduced inflammation, plasma 
levels of the anti-inflammatory cytokine IL-10 were increased in 
miR-210 KO versus control mice (Fig. 6K). MiR-210 deletion in 
macrophages did not alter their infiltration into the liver (fig. S3D) 
while neutrophil accumulation in response to LPS was reduced, 
the latter being another sign of a milder inflammatory response 
(fig. S3E).
Several signs of reduced inflammation were also found during the 
course of T. brucei infection. Splenic macrophages from miR-210 KO 
chimeras displayed a lower induction or no induction of the proin-
flammatory markers MHC-II, iNOS, and TNF-, as assessed by 
FACS both in the acute (day 7) and in the late (days 18 and 26) stage 
of the infection (Fig. 7, A to C). Along the same line, serum levels of 
TNF- and macrophage migration inhibitory factor (MIF), promi-
nent inflammatory mediators during T. brucei infection (36, 37), 
were lower in miR-210 KO versus WT chimeras (Fig. 7, D and E). Con-
versely, the anti- inflammatory cytokine IL-10 showed significantly 
higher plasma levels in miR-210 KO chimeras (Fig. 7F). Moreover, 
in the acute stage of the disease, the plasma levels of the antimicrobi-
al and anti- inflammatory metabolite itaconate were found to be higher 
in miR-210 KO versus WT chimeras (Fig. 7G). Despite a change in 
phenotype, post-infection macrophage numbers in the spleen of 
miR-210 KO chimeras were following the same trend as in control 
animals during the infection (fig. S3F). Aligned with a faster resolution 
of the inflammatory response, neutrophilia was reduced in miR-210 
KO versus WT chimeras at the late stage (i.e., day 26 after infection) but 
not at the early stage after infection (i.e., until day 18 after infection) 
(Fig. 7H). Overall, miR-210 deletion in macrophages leads to a gen-
erally reduced inflammatory response because of the incomplete 
skewing toward the M1 status, overall explaining the increased sur-
vival to endotoxin-mediated septic shock and T. brucei infection.
Fig. 5. ISCU modulation by miR-210 mediates the metabolic rewiring in LPS/
IFN-–stimulated macrophages. (A) ISCU protein levels (Western blot) in WT and 
miR-210 KO BMDMs (left) and in WT BMDMs electroporated with pre-control (pre-
miR-CTRL) or miR-210 precursor (pre-miR-210) (right). The percentage attached to 
the blot indicates densitometric changes. (B to E) A representative OCR curve (B) 
and activity of complex I (C), complex II (D), or complex IV (E) (seahorse) on permea-
bilized WT and miR-210 KO BMDMs after 42-hour LPS/IFN- stimulation in the pres-
ence of pyruvate (Pyr) and malate (Mal). Rotenone, succinate, antimycin A, or TMPD + 
ascorbate was injected at the indicated time point. Complex activities in (C) to (E) 
were calculated by OCR subtractions. BMDMs were electroporated 24 hours before 
LPS/IFN- treatment with two siRNAs against ISCU or a control sequence. (F) Extra-
cellular lactate concentration (colorimetric assay) in the medium of WT and miR-210 
KO BMDMs, after 24-hour LPS/IFN-. BMDMs were electroporated 48 hours before 
LPS/IFN- treatment with two siRNAs against ISCU or a control sequence. Data were 
normalized by protein content (B to F). Data show a representative of two (A) or a 
pool of two (B to E) or four (F) independent experiments. P value was assessed by 
two-way ANOVA with Tukey’s multiple comparisons test (A to F). Statistical analysis: 
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Regulation of miR-210 in human monocytes 
and macrophages might represent a diagnostic 
and prognostic biomarker for sepsis
In an attempt to investigate the relevance of our mouse data in a 
human setting, we first differentiated blood-circulating monocytes 
isolated from healthy volunteers into proinflammatory hMDMs (38, 39). 
Real-time analysis on hMDMs showed a significant up-regulation 
of miR-210 upon LPS/IFN- treatment, phenocopying what was ob-
served in murine macrophages (Fig. 8A). Subsequently, we silenced 
miR-210 levels by the transfection of hMDMs with an anti-miR-210 
LNA observing an increased level of ISCU protein (Fig. 8B). Con-
versely, transfection with the miR-210 precursor resulted in a reduc-
tion of ISCU at the protein level, compared to a relative precursor 
control (Fig. 8C).
Since the up-regulation of miR-210 was already observed in mouse 
monocytes after LPS challenge, we measured miR-210 expression 
in human blood-circulating monocytes as well and assessed whether 
its levels were correlating with sepsis. In this regard, we isolated 
Fig. 6. MiR-210 deletion in macrophages counters inflammatory pathways and activation markers in response to endotoxin. (A and B) Top 10 GO terms enriched, 
based on gene ratio, for significantly down-regulated (A) and up-regulated (B) genes in miR-210 KO versus WT BMDMs after 42-hour LPS/IFN- stimulation. Color of the 
dots indicates adjusted P value. (C and D) MFI of major histocompatibility complex class II (MHC-II) (C) and inducible nitric oxide synthase (iNOS) (D) of WT and miR-210 
KO BMDMs, untreated or after 24-hour LPS/IFN-. (E) IL-6 concentration (MSD) in the medium of WT and miR-210 KO BMDMs, untreated or after 12-hour LPS/IFN-. 
(F) Fold changes of IL-6 [enzyme-linked immunosorbent assay (ELISA)] in the medium of WT and miR-210 KO BMDMs after 24-hour LPS/IFN-. BMDMs were electroporated 
48 hours before LPS/IFN- treatment with 2 siRNAs against ISCU or a control sequence. (G) MFI of MHC-II of WT and miR-210 KO BMDMs after 24-hour LPS/IFN-. Macro-
phages were transduced with a short hairpin RNA against ISCU or a control sequence. (H) MFI of MHC-II in liver macrophages (CD45+, CD11b+, Ly6G−, and F4/80+) from 
control (n = 9) and miR-210 M0 (n = 9) mice. (I) MFI of MHC-II in spleen macrophages (CD45+, CD11b+, Ly6G−, and MHC-II+) from control (n = 9) and miR-210 M0 (n = 10) 
mice. (J and K) IL-6 and IL-10 concentration (ELISA) in the plasma of control (n = 9 to 13) and miR-210 M0 (n = 10 to 11) mice. In vivo analysis was performed 18 hours 
after sublethal LPS intraperitoneal injection (H to K). Data show a representative of three (C and D) or a pool of two (E and H to K), three (F), or five (G) independent exper-
iments. P value was assessed by two-way ANOVA with Sidak’s multiple comparisons test (C to G) and two-tailed, unpaired, Student’s t test (H to K). Statistical analysis: 
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circulating monocytes from the blood of patients with sepsis re-
cruited in the Oncology Unit (“cancer and sepsis”), cancer patients 
with no sign of sepsis (“cancer”), and healthy volunteers (“healthy”) 
(table S2). MiR-210 levels in circulating monocytes were much 
higher in oncological patients with sepsis compared to either cancer 
patient controls or healthy volunteers, but there was almost no 
difference between cancer only and healthy conditions (Fig. 8D). 
This result offers a “proof of concept” that monocyte-derived miR-
210 might represent a diagnostic biomarker for human sepsis, 
which might discriminate for other inflammatory conditions such 
as cancer.
Fig. 7. MiR-210 deletion reduces macrophage type 1 responses and overall 
inflammation during T. brucei infection. (A to C) MFI from WT➔WT and miR-210 
KO➔WT of MHC-II (day 0, n = 5 and 5; day 7, n = 8 and 7; day 18, n = 5 and 5; day 26, 
n = 5 and 5) (A), iNOS (day 0, n = 5 and 5; day 7, n = 8 and 7; day 18, n = 5 and 5; day 
26, n = 5 and 5) (B), and TNF- (day 0, n = 4 and 4; day 7, n = 8 and 7; day 18, n = 5 
and 5; day 26, n = 5 and 4) (C) in splenic macrophages (CD45+, CD11b+, Ly6G−, 
F4/80+, and MHC-II+) before (day 0) or 7, 18, and 26 days after T. brucei infection. 
(D to F) TNF- (D), MIF (E), and IL-10 (F) concentration (ELISA) in the plasma of 
WT➔WT and miR-210 KO➔WT chimeric mice before (day 0) or 7 and 26 days 
after T. brucei infection (day 0, n = 5 and 5; day 7, n = 8 and 7; day 26, n = 7 and 7). 
(G) Itaconate levels (LC-MS) in the plasma of WT➔WT and miR-210 KO➔WT chimeric 
mice before or 7 days after T. brucei infection (day 0, n = 4 and 4; day 7, n = 8 and 7). 
(H) Percentage (FACS) of splenic neutrophils (CD45+, CD11b+, and Ly6G+) of 
WT➔WT and miR-210 KO➔WT chimeric mice before (day 0) or 6, 18, and 26 days 
after T. brucei infection (day 0, n = 4 and 4; day 7, n = 8 and 7; day 18, n = 5 and 5; day 26, 
n = 7 and 7). Data are representative of two independent experiments (A to F and 
H). P value was assessed by multiple Student’s t test (A to F and H) and by two-way 
ANOVA with Sidak’s multiple comparisons test (G). Statistical analysis: *P < 0.05; 
**P < 0.01; ***P < 0.001; graphs show means ± SEM.
Fig. 8. MiR-210 is up-regulated and released by human macrophages and circu-
lating monocytes upon pathogenic stimuli. (A) MiR-210 levels (qRT-PCR) in hMDMs 
untreated or after 24-hour LPS/IFN- stimulation. (B and C) ISCU protein levels 
(Western blot) in hMDMs transfected with anti–miR-210 or scramble LNAs (B), and 
miR-210 precursor (pre-miR-210) or relative control (pre-miR-CTRL) (C). The percentage 
attached to the blot indicates densitometric changes. (D) MiR-210 levels (qRT-PCR) 
in circulating CD14+ monocytes isolated from the blood of healthy volunteers (n = 13) 
and cancer (cancer patients with no sepsis, n = 13) and oncological patients with sepsis 
(cancer patients with sepsis, n = 11). (E) MiR-210 levels (qRT-PCR) in the conditioned 
medium from hMDMs, untreated or after 24-hour LPS/IFN-. (F) Circulating miR-210 
levels (qRT-PCR) in serum of patients with sepsis who will survive (survivors, n = 18) or 
die (nonsurvivors, n = 18). (G) Following pathogen interaction, both circulating mono-
cytes and macrophages up-regulate miR-210. MiR-210 represses ISCU and (probably) 
other target genes contributing to the metabolic rewiring of macrophages toward 
glycolysis, required for the inflammatory burst, at the expense of mitochondrial respi-
ration and itaconate production, ultimately leading to an exacerbated inflammatory re-
sponse detrimental for the organism. In contrast, blocking miR-210 in macrophages, 
pharmacologically or genetically, unleashes the expression of ISCU and potentially other 
targets, impeding a full glycolytic-dependent M1-like activation state and displaying a 
milder proinflammatory response but earlier itaconate production, favoring pathogen 
control and altogether improving disease outcome. Data are representative of two 
independent experiments (A to C and E). P value was assessed by two-tailed, unpaired, 
Student’s t test (A, B, E, and F) and one-way ANOVA with Tukey’s multiple comparisons 
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Soluble markers of sepsis are so far missing. It has been recently 
demonstrated that miR-210 can be found in the exosomes of a trans-
formed cell line of macrophage origin (40). Therefore, we checked 
whether the levels of miR-210 in the medium mirrored its expres-
sion in macrophages. Here, we found that miR-210 up-regulation 
in response to the treatment of BMDMs with LPS/IFN- led to a 
similar increase of miR-210 in the culture medium (fig. S4A). Simi-
larly, miR-210 levels were up-regulated in the plasma of WT mice in 
response to LPS (fig. S4B), but this induction was prevented when 
challenging miR-210 M0 mice (fig. S4C), suggesting an important 
contribution of monocyte/macrophage in plasma miR-210 levels 
upon inflammatory/infectious stimuli.
Mirroring the mouse scenario, miR-210 was also detected in the 
culture medium of hMDMs upon LPS/IFN- treatment, leading to 
enhanced levels of secreted miR-210 in the culture medium (Fig. 8E). 
Encouraged by these data, we checked circulating miR-210 levels in 
a different cohort of patients who were admitted at the intensive care 
unit (ICU) with sepsis (table S3). Here, we found that miR-210 levels 
in serum correlated with disease outcome, being strongly up-regulated 
in the nonsurvivors (Fig. 8F). Although larger cohorts and prospec-
tive studies are warranted, these data argue that circulating miR-210 
might represent a prognostic soluble biomarker in human sepsis.
DISCUSSION
Macrophage activation results in the prompt up- and down-regulation 
of a wide pattern of genes and metabolic pathways to mount a proper 
immune response to infections (4, 5). This entire process, still not 
entirely understood, must be tightly regulated since its loss of con-
trol can lead to deadly inflammatory conditions such as sepsis (35).
Here, we show that macrophages up-regulate miR-210 in response 
to Gram-negative or Gram-positive bacteria, parasitic T. brucei in-
fection, and SARS-CoV-2 (or, at least, to some of their components) 
through HIF-1 stabilization, suggesting the involvement of miR-
210 in a wide range of host-pathogen interactions. The relevance of 
miR-210 in different diseases ranging from endotoxemia to bacteria 
(polymicrobial and S. pneumoniae) and parasite (T. brucei) infections 
was further confirmed by our in vivo data. While IFN- and LPS 
binding to, respectively, IFN-R and Toll-like receptor 4 (TLR4) leads 
to synergic HIF-1 accumulation through JAK/STAT1 (Janus kinase/
signal transducer and activator of transcription 1) (23, 41) and NF-B 
(nuclear factor B) activation (42), previous literature suggests that 
the S. pneumoniae surface lipoprotein diacylglycerol transferase (43) 
and CpG motifs in the trypanosomal genomic DNA (44) may ac-
count for a similar effect via TLR2 and TLR9, respectively. It is likely 
that the relevance and abundance of the TLR family members in 
macrophages and monocytes (4) confer the selectivity of miR-210 
up-regulation in these specific immune cell types.
Our in vitro analysis reveals that miR-210 up-regulation enables 
the effectiveness of the glycolytic switch imposed by LPS through 
the efficient shutdown of cell respiration. This effect was greatly 
achieved by the down-regulation of ISCU by miR-210 as proven by 
the observation that ISCU silencing in miR-210 KO macrophages 
reduced the OCR and, indirectly, increased glycolysis, thus re- 
establishing metabolic features of WT macrophages upon LPS/INF- 
stimulation. A possibility is that a reduction in NO and an increase 
in IL-10 levels associated with the phenotypic skewing of miR-210 
KO macrophages can install a positive feedback loop that, indi-
rectly, facilitates OXPHOS (45, 46). A previous study has shown that 
the shift from OXPHOS to aerobic glycolysis is a crucial mechanism 
for the initial activation of innate immunity in patients with sepsis 
(47). In addition to OXPHOS regulation, ISCU modulation by 
miR-210 might partly explain the improved pathogen clearance 
displayed in vivo by macrophage-specific miR-210–deficient mice. 
Previous results have already shown that repression of ISCU by 
miR-210  in endothelial cells reduces the activity of aconitase, an-
other Fe-S cluster protein (33). Here, we argue that itaconate, a po-
tent antimicrobial and anti-inflammatory intracellular and secreted 
metabolite (7, 29, 48, 49), is promptly and highly induced in activated 
miR-210–deficient macrophages via the enhanced channeling of 
glucose carbons down to the immune-responsive gene 1 (Irg1) path-
way. Itaconate production by cis-aconitate-decarboxylase (the en-
zyme codified by the gene Irg1) may then contribute not only to the 
protection against the immunopathology of several infectious dis-
eases observed in our in vivo model but also to the enhanced patho-
gen control observed in the S. pneumoniae and, to less extent, in the 
T. brucei infection models. We cannot exclude the idea that other 
macrophage-related mechanisms such as pathogen killing, diges-
tion, and phagocytosis might be involved (50). Consistent with the 
fact that miR-210 controls other metabolic genes, e.g., NDUFA4 
(15) and PDK1 (51), and also affects metabolic and nonmetabolic 
pathways, e.g., AKT/mTOR (52) and NF-B signaling (18, 53), 
when silencing ISCU in miR-210–deficient macrophages, we could 
observe reversion of some, but not all, the immunological features 
such as increased IL-6 and MHC-II levels. This highlights the com-
plex network of genes and pathways undermined by miRs and the 
impossibility to consider miR-210 as epistatic to ISCU only.
Following pathogen interaction, both circulating monocytes and 
macrophages up-regulate miR-210, which “imprints” macrophages 
toward an M1 activation state. Subsequently, these activated macro-
phages continue to exacerbate their proinflammatory response in a feed- 
forward loop as long as they remain in contact with the pathogen, 
thus decreasing the possibility of the organism to recover from the 
disease (Fig. 8G). Our in vitro proteomic and transcriptomic ap-
proaches as well as flow cytometric and ELISA analysis, both in vi-
tro and in vivo, have consistently revealed that depletion of miR-210 
mitigates this inflammatory, type 1 response upon activation, ac-
companied by an overt metabolic change in macrophages. At the 
same time, miR-210 ablation does not entirely impair the M1-type 
response and, therefore, infection does not take over (as we show in 
experimental CLP, or in case of T. brucei and S. pneumoniae infec-
tion) and, in contrast, pathogen control is even improved. On the 
other hand, miR-210 deletion does not seem to enforce the critical 
pathways characterizing an anti-inflammatory M2 response. Only 
one branch of the proteomic analysis highlighted terms related to 
protein localization. This could be intuitively associated to chaper-
one pathways, ER stress, and unfolded protein responses, which are 
more commonly associated to M2 macrophage polarization (54).
Overall, our findings suggest that pathogen-macrophage inter-
action imposes a deemed glycolytic switch that is sustained by HIF-
1 accumulation (55, 56). More in detail, HIF-1 plays a dual role 
in macrophages: It induces glycolytic gene expression, e.g., LDH, PDK, 
HK2, PFK1, and G6PD (55), and, as we show, represses oxidative 
metabolism through the induction of miR-210, altogether permit-
ting glycolysis that is instrumental for the inflammatory burst. This 
entire cascade is essential for macrophage responses determining 
disease outcome. Besides our in vivo phenotypic data, this model is 
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macrophages such as PKM2 confers resistance to endotoxemia by 
affecting inflammatory responses (57, 58). Consistently, loss of func-
tion (56, 59) or gain of function (60) for HIF-1 have been proven to, 
respectively, mitigate and enhance macrophage-mediated inflam-
matory responses.
On one hand, all our data reinforce and complement the role of 
miR-210 in regulating oxidative metabolism and, in turn, glycolysis 
consistently with previous reports in cancer cells (15–17) or in mus-
cle tissue during ischemia (12). On the other hand, they highlight 
different functional consequences of miR-210 modulation that are 
clearly cell and context/disease dependent (53, 61, 62) revealing its 
involvement in infectious diseases and sepsis.
At this point in time, we are not able to exclude an exocrine or 
paracrine mechanism of miR-210. MiR-210 was detectable in the 
extracellular milieu of LPS-stimulated murine or human macro-
phages and in the plasma of both septic mice and patients. Released 
miR-210, free or in exosomes, might regulate (metabolic) gene ex-
pression of neighboring cells as shown, for miR-210 (40) and other 
miRs (8, 63, 64) in different contexts.
Since miR-210 might be a suitable biomarker or therapeutic tar-
get, our study could also have social and medical impact. It is esti-
mated that sepsis accounts for about 11 million deaths in 2017 (65) 
and, accordingly with WHO reports, lower respiratory infections 
are still the fourth global cause of death. Currently, the identifica-
tion and monitoring of sepsis is still extremely challenging (66) and 
no targeted therapies are available in clinical practice (67). To ren-
der the clinical scenario even more complex, sepsis can occur in 
patients with multiple comorbidities (66). For example, it is esti-
mated that almost 10% of cancer deaths are associated with sepsis 
(3). In our pilot study, miR-210 levels are specifically increased in 
monocytes isolated from patients with septic cancer but not in those 
with only cancer, suggesting its potential diagnostic value as a dis-
criminant biomarker. In a different cohort of patients, individuals 
that exhibited the highest miR-210 serum levels are the ones that 
ultimately will succumb because of sepsis. Overall, these findings 
could be exploited for on-time medical intervention or to steer de-
cisions in terms of treatment follow-up/discontinuation, thus in-
creasing the possibility for the patient to survive and preventing 
costly procedures at the ICU. In addition, the implementation of a 
theragnostic approach would allow stratifying the patients based on 
miR-210 expression levels to select those patients who may benefit 
more from miR-210 inhibition. We show that a single injection of 
anti–miR-210 LNA strongly impairs miR-210 expression in macro-
phages, which is associated with an increase in survival after endo-
toxemia. The therapeutic benefit of an LNA against miR-122 is 
currently tested in a clinical trial for the treatment of hepatitis C 
virus infections (27), underlying the feasibility of this approach and 
translational aspect of our data.
Several studies have indicated that the overwhelming inflamma-
tory response to SARS-CoV-2 infection dictates disease severity 
and survival hypothesizing that a mechanism of viral sepsis could 
occur (68). In this regard, a strong hyperinflammatory response of 
monocytes/macrophages was found in the severe cases of patients 
with COVID-19 (coronavirus disease 2019) (69). More recently, the 
increased cytokine production in monocytes was found to be medi-
ated by a glycolytic switch orchestrated by HIF-1 (26). In view of 
our observation that miR-210 is induced in macrophages upon ex-
posure to the SARS-CoV-2 spike protein, one could argue that miR-
210 takes part in this HIF-1–mediated metabolic reprogramming, 
suggesting the possible involvement of this miR in the pathogenici-
ty of the disease (as we have shown for the other infectious/septic 
models) that could be further investigated. In addition, in our 
hands, induction of miR-210 upon macrophage interaction with the 
spike protein of SARS-CoV-2 alone is able to trigger inflammatory 
(but not anti-inflammatory) responses, which altogether is aligned 
with our model.
In conclusion, we identify miR-210 as a nongenetic immunoreg-
ulator, an “inflammo-miR,” induced in response to invading patho-
gens to enable a specific metabolic reprogramming required for 
macrophage activation and for their switch toward a proinflamma-
tory, M1 phenotype. At large, these findings provide insights for the 
treatment, detection, and management of several diseases charac-
terized by the over-reaction of the immune system to the entry of 
viruses, bacteria, and parasites.
MATERIALS AND METHODS
Mice
C57BL/6 miR-210 floxed mice were obtained in collaboration with 
M. Ivan (70) (University of Indiana, USA). Briefly, miR-210 floxed 
mice were crossed to Gata-1 Cre mice to constitutively delete the 
MiR210 locus, obtaining miR-210 KO mice. Alternatively, miR-210 
floxed mice were intercrossed with the tamoxifen-inducible, 
macrophage-specific CSFR1:Cre-ERT (iCre) deleter mouse line (a gift 
of J. W. Pollard, University of Edinburgh, UK) obtaining miR-210 
M0 (iCre-positive mice) mice and controls (iCre-negative mice). 
In the latter model, the deletion of miR-210 was induced by daily 
tamoxifen (T5648, Sigma-Aldrich) administration (40 mg/kg) by 
gavage (for the LPS-induced endotoxin model) or intraperitoneally 
(for the S. pneumoniae infection model) in 100 l of a solution con-
taining 87.5% sunflower oil and 12.5% EtOH for 5 days. Moreover, 
there was an additional administration at day 0 and 18 hours after 
LPS injection to induce deletion of miR-210  in newly recruited 
macrophages. Control mice were treated with tamoxifen according 
to the same protocol. In all the experiments, littermate controls 
were used. Housing and all experimental animal procedures were 
approved by the Institutional Animal Care and Research Advisory 
Committee of the KU Leuven. For all experiments with T. brucei, 
maintenance and care of the mice complied with the European 
Convention for the Protection of Vertebrate Animals used for Ex-
perimental and Other Scientific Purposes guidelines (CETS n° 123) 
and were approved by the Ethical Committee for Animal Experi-
ments at the Vrije Universiteit Brussel (permit numbers: 14-220-05).
Bone marrow chimera generation 
and hematological analysis
C56BL/6 recipient mice were sublethally irradiated with 9.5  Gy 
(gray) and subsequently received up to 1 × 107 bone marrow cells 
from WT and miR-210 KO mice via tail vein injections to generate 
WT and miR-210 KO chimeric mice. Reconstitution of the bone 
marrow was allowed for 6 weeks. Red and white blood cell count 
was determined using a hemocytometer on peripheral blood col-
lected in heparin with capillary pipettes by retro-orbital bleeding.
LPS-induced endotoxemia
Eight- to 12-week-old mice were injected with a single shot of LPS 
Escherichia coli 0111:B4 (20 to 27.5 mg/kg; L2630, Sigma-Aldrich). Mice 
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was monitored after 18 hours. Blood was taken via retro-orbital 
puncture and combined with an anticoagulant, e.g., lithium-heparin. 
Plasma preparation for LDH and creatinine analysis was obtained 
by centrifugation of the blood for 10 min at 2000g (4°C) and after-
wards sent to the clinical laboratory of UZ Leuven, which per-
formed the analysis.
In vivo (and in vitro) downmodulation of miR-210 was carried 
out as previously described (12). Briefly, 200 l of phosphate-buffered 
saline (PBS)–diluted LNA oligonucleotides (12 mg/kg) against miR-
210 (anti–miR-210) or SCR control sequence was injected into the 
tail vein; 15-mer LNA-enhanced sequences with complete phos-
phothioate backbone were used: anti-miR-210, GCTGTCACACG-
CACA; SCR, CGTCTAGCCACCTAG (in vivo LNA-miR inhibitors; 
Exiqon). The injection of LNA oligonucleotides was performed 
48 hours before LPS injection.
Cecal ligation and puncture
The CLP procedure was performed according to the general guide-
lines (19). Briefly, mice were anesthetized by isoflurane inhalation, 
and a 1-cm incision was made in the abdomen after which the 
cecum was exposed and ligated. Subsequently, two punctures were 
made in the cecum with a 21-G needle for induction of a lethal 
CLP. The abdominal musculature and skin were closed with run-
ning sutures and metallic clips, respectively. After 10 and 24 hours 
from the surgery, mice were injected intraperitoneally with an anti-
biotic cocktail containing ceftriaxone (25 mg/kg; Sigma-Aldrich) 
and metronidazole (12.5 mg/kg; Sigma-Aldrich) dissolved in 200 l 
of PBS. Rectal body temperature was monitored.
T. brucei infection
Clonal pleomorphic T. brucei AnTat 1.1E parasites were a gift from 
N. Van Meirvenne (Institute for Tropical Medicine, Belgium) and 
stored at −80°C. Mice were intraperitoneally infected with 5 × 103 
AnTat1.1E trypanosomes. Parasite and red blood cell (RBC) num-
bers in blood were determined via a hemocytometer by tail cut 
(2.5 ml of blood in 500 ml of RPMI). Anemia was expressed as per-
centage of RBCs remaining in infected mice compared to that of 
noninfected mice.
S. pneumoniae infection
Mice were anesthetized intraperitoneally with ketamine (60 mg/kg, 
Ketavet, Zoetis) and medetomidine hydrochloride (0.8 mg/kg; Domitor, 
Orion Pharma). Each mouse received 107 CFUs of S. pneumoniae 
serotype 2 D39 strain via intratracheal instillation followed by sub-
cutaneous injection of atimepazole hydrochloride (0.8 mg/kg; 
Antisedan, Orion Pharma) 30 min after infection. Twenty hours 
after infection, the animals were euthanized, and blood was ob-
tained from the abdominal artery. The left lung was harvested and 
homogenized under sterile conditions by using a tissue homogenizer 
(Bullet Blender) and lysing tubes (Precellys). Tenfold serial dilutions 
were plated from blood and left lung homogenate into blood agar 
plates and grown overnight at 37°C and 5% CO2, and CFU counts 
were determined.
Histology and immunostaining
Livers and kidneys from septic mice were dissected, paraffin-embedded, 
and sectioned at 8-m thickness. For TUNEL stainings, liver sec-
tions were stained using the ApoTag Plus Peroxidase In Situ Apoptosis 
Detection Kit (Chemicon) according to the manufacturer’s directions. 
Hematoxylin was used as a nuclear stain. Apoptosis was quantified 
as TUNEL-positive cells per optical field. Eight fields (20×) per liver 
were selected in a blinded fashion for quantification. For periodic 
acid–Schiff stainings, kidney sections were incubated for 10 min in 
periodic acid solution (2 g of H5IO6 in 200 ml of AD) after deparaf-
finization. After rinsing several times in tap water for 3 min, sec-
tions were incubated in Schiff’s reagent (Prosan) for 20 min and 
washed for 10 min under tap water. Last, sections were incubated in 
Harris’s hematoxylin (BDH) for 10 s and again rinsed under tap water 
for 10 min. The last steps were dehydration and mounting. Staining 
was performed to determine the glycogen-positive area in the kidney. 
Eight fields (20×) per kidney were selected in a blinded fashion for 
quantification.
Flow cytometry
To proceed with the FACS staining, a single-cell suspension was 
obtained from spleen and liver, as previously described (20). Cells 
in the peritoneal cavity were isolated by lavage as indicated in the 
section below, while peripheral blood was collected with heparin-
ized capillary pipettes by retro-orbital bleeding. For the blood, and 
when required, RBC lysis was performed using Hybri-Max (Sigma- 
Aldrich). Cells were resuspended and counted in FACS buffer [PBS 
containing 2% fetal bovine serum (FBS) and 2 mM EDTA]. Subse-
quently, cells were incubated for 15 min with purified rat anti- mouse 
Fc blocking monoclonal antibody (Clone 2.4G2, BD-Pharmingen). 
The surface staining was performed, in the dark, at 4°C for 30 min 
using the following antibodies: viability dye (Invitrogen), anti-CD45 
(30-F11, eBioscience), anti-CD11b (M1/70, eBioscience), anti-F4/80 
(BM8, eBioscience), anti-MHC-II (M5/114.15-12, eBioscience), anti- 
Ly6C (AL-21, BD Pharmingen), anti-Ly6G (1A8, BD Pharmingen), 
anti-CD115 (AFS98, BioLegend), anti-TCRb (H57-597, BD Biosci-
ences), anti-CD45/B220 (RA3-6B2, BD Biosciences), and anti- CD90.1 
(Thy-1.1) (OX-7, BioLegend). After surface staining, cells were 
washed once with FACS buffer and resuspended in FACS buffer for 
FACS analysis. For iNOS intracellular staining in vitro on BMDMs, 
after surface staining (see before) and one washed with FACS buf-
fer, cells were resuspended and incubated, in the dark, at 4°C for 
30  min in Fix/Perm buffer (00-5523, eBioscience), prepared ac-
cording to the manufacturer’s instructions. After one wash with 
permeabilization buffer (00-5523, eBioscience), cells were stained 
in permeabilization buffer overnight with anti-NOS2 (CXNFT, 
Thermo Fisher Scientific). For intracellular staining for iNOS or 
TNF- on cells isolated from the spleen, cells were cultured in 
RPMI-medium + 5% fetal calf serum with brefeldin A (BD Bio-
science). Four hours later, cells were washed with FACS buffer 
and subjected to surface staining (see before). After washing with 
FACS buffer, the cells were incubated, in the dark, at 4°C for 
30 min in Fix/Perm buffer (00-5523, eBioscience), prepared ac-
cording to the manufacturer’s instructions. After one wash with 
permeabilization buffer (00-5523, eBioscience), cells were stained 
in permeabilization buffer with anaphase-promoting complex 
(APC)–conjugated anti–TNF- (MP6-XT22, BioLegend) or unla-
beled rabbit iNOS (M19, BD Biosciences) and APC-conjugated 
anti-rabbit immunoglobulin G (eBioscience) for 30 min at 4°C in 
the dark. Cells were subsequently washed in permeabilization buf-
fer and resuspended in cold permeabilization buffer for further 
FACS analysis. Cells were sorted by a FACSAria III (BD Biosci-
ences) or acquired on a FACSVerse or FACSCanto II (BD Biosci-
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Peritoneal lavage
Mice were euthanized and 6 ml of PBS was injected into the perito-
neal cavity using a 27-G needle. The abdomen was softly rubbed for 
1 to 2  min and disinfected with 70% ethanol. Peritoneal cells 
were collected by inserting a syringe via a 24-G needle. For in vitro 
analysis on peritoneal macrophages, retrieved cells were counted 
and seeded in nontreated culture dishes non–tissue culture–treated 
dishes for the respected experiments. One hour after, cells were vig-
orously washed three times with PBS to enrich for peritoneal mac-
rophages. For in vitro experiments, peritoneal macrophages were 
stimulated for the reported amount of time with LPS (100 ng/ml), 
IFN- (20 ng/ml), IL-4 (10 ng/ml), or IL-13 (10 ng/ml) in the differ-
ent indicated combinations. For flow cytometry analysis, retrieved 
cells were counted and resuspended in FACS buffer (PBS con-
taining 2% FBS and 2 mM EDTA) and further processed for flow 
cytometry.
Bone marrow–derived macrophages
Macrophages were derived from bone marrow precursors as de-
scribed before (71). Briefly, bone marrow precursors (up to 10 × 
106 cells) were cultured in a volume of 6 ml in a 10-cm petri dish 
(nontreated culture dishes, bacterial grade) in Dulbecco’s modified 
Eagle’s medium (DMEM) high glucose (41965039, Gibco) supple-
mented with 20% FBS, 30% L929 conditioned medium as a source 
of M-CSF, 25 mM Hepes, 2 mM l-glutamine, and Pen/Strep. After 
3 days of culture, an additional 3 ml of differentiation medium was 
added. At day 7, macrophages were detached with ice-cold PBS. The 
obtained cells were a uniform population of macrophages as as-
sessed by FACS, using the pan-macrophage–specific marker F4/80. 
For in vitro experiments, BMDMs were stimulated for the reported 
amount of time with LPS (100 ng/ml), IFN- (20 ng/ml), IL-4 
(10 ng/ml), and T. brucei lysate (5 g per 1 × 106 of BMDMs) in the 
different indicated combinations. For coculture experiments with 
heat-killed bacteria, a ratio of 1:10 (macrophage:bacteria) was used. 
BMDMs were cultured in DMEM high glucose (41965039, Gibco), 
10% FBS, 2 mM l-glutamine, and Pen/Strep.
Generation of heat-killed P. aeruginosa and S. pneumoniae 
and T. brucei lysates
Both P. aeruginosa PAO-1 strain and S. pneumoniae serotype 2 D39 
strain were exponentially grown in nutrient broth (Oxoid) at 37°C 
in the case of P. aeruginosa and brain/heart infusion broth (Oxoid) 
supplemented with 20% of heat-inactivated FBS (Gibco) at 37°C, 
5% CO2. Heat killing was achieved by immersion of the bacteria 
in a water bath for 1 hour at 80°C. For the in vitro stimulation of 
cells with parasite lysate, parasites were isolated as described. Brief-
ly, mice with a systemic T. brucei (AnTat1.1E) parasitemia were 
exsanguinated and parasites were purified from heparinized blood 
by diethylaminoethyl-cellulose (DE-52, Whatman). Parasites were 
collected in the flow-through and centrifuged for 10 min at 805g 
(Eppendorf 5810R centrifuge) and washed two times with PBS. 
Last, the pellet was resuspended in 1 to 2 ml of PBS. The lysate was 
prepared by three repetitive freeze-thawing cycles (−80°C, 37°C). 
The concentration of the lysate was determined spectrophotometri-
cally (Nanodrop) following Prosep-Remtox treatment (Immuno-
source, Schilde, Belgium), and the samples were confirmed to be 
LPS free by using the Limulus Amebocyte Lysate Kinetic-QCL 
Kit (Cambrex, East Rutherford, NJ, USA) in accordance with the 
manufacturer’s instructions.
Spike-in SARS-CoV-2 stimulation
hMDMs differentiated with M-CSF were cultured in RPMI medium 
with SARS-CoV-2 (2019-nCoV) Spike protein (S1 + S2 ECD-His 
Recombinant Protein; Sino Biological, 40589-V08B1) at a concen-
tration of 2 g/ml.
RNA extraction, reverse transcription, and RT-qPCR
Cells were lysed and total RNA was isolated according to the man-
ufacturer’s instructions using the Cell and Plant Kit (no. 300110, 
Exiqon) or miRNeasy Mini Kit (217004, Qiagen). Before RNA iso-
lation from human serum or mouse plasma samples [blood collect-
ed in EDTA and centrifuged 10 min at 2000 rpm (4°C)] or culture 
media [5 min, 300g (4°C)], 10 fmol of C. elegans miR cel-miR-39 
spiked-in (21960, Qiagen) was added to 20 l of each sample, as 
previously described (72) and used for normalization. Reverse tran-
scription was performed using the TaqMan MicroRNA Reverse 
Transcription Kit (4366597, Applied Biosystems) and the specific 
RT primers from the miR assays according to the manufacturer’s 
instructions. Reverse transcription to cDNA was performed with the 
SuperScript III First Strand cDNA Synthesis Kit (18080051, Thermo 
Fisher Scientific) according to the manufacturer’s protocol. The cDNA, 
primer/probe mix, and TaqMan Fast Universal PCR Master Mix were 
prepared in a volume of 10 l according to the manufacturer’s instruc-
tions (Applied Biosystems). TaqMan primers/assays used are hsa-
miR-210-3p (000512, Thermo Fisher Scientific), U6-snRNA (001973, 
Thermo Fisher Scientific), and cel-miR-39 (000200, Thermo Fisher 
Scientific), while for gene detection, pre-made assays were purchased 
from IDT (HPRT, Hs.PT.58v.45621572; HIF1A, Hs.PT.56a.534274.g; 
IL6, Hs.PT.58.40226675; TNFA, Hs.PT.58.45380900; and IL10, 
Hs.PT.58.2807216). Samples were loaded into an optical 96-well Fast 
Thermal Cycling plate (Applied Biosystems) and quantitative 
real-time PCR (qRT-PCR) was performed using an ABI Prism 7500 
Fast Real-Time PCR System (Applied Biosystems).
Electroporation for siRNA and precursor miR-210 delivery
Briefly, 5.6 × 106 BMDMs were resuspended in 750 l of Opti-MEM 
and were electroporated (250 V, 950 F, ∞ ) with 120 pmol of 
siRNA HIF-1 (mm.Ri.Hif1a.13.1 IDT), scrambled negative con-
trol (51-01-19-09, IDT), with 60 pmol of two siRNAs for ISCU 
(mm.Ri.Iscu.13.1 and mm.Ri.Iscu.13.2 IDT), or with 40 nM (hMDMs) 
or 150 nM (BMDMs) of Pre-miR miR-210 miR Precursor (PM10516, 
Thermo Fisher Scientific) or Pre-miR miR Precursor Negative Con-
trol (AM17100, Thermo Fisher Scientific).
shRNA-mediated silencing
A short hairpin RNA (shRNA) sequence for Iscu (CGTCATGAAACT-
GCAGATCCA) was subcloned in a lentiviral pLKO3 Thy1.1 vector 
backbone, and an shRNA sequence for LacZ was used as control 
(GTTCCGTCATAGCGATAACGA). Amplified viral particles were 
purified and titrated, and subsequently used for transduction. Briefly, 
2 × 106 bone marrow cells in a six-well plate were transduced at 
day 5 of differentiation in DMEM high glucose (41965039, Gibco) 
supplemented with 20% FBS, 2 mM l-glutamine, and Pen/Strep 
with polybrene (16 mg/ml) overnight. Then, the medium was re-
placed with DMEM high glucose (41965039, Gibco) supplemented 
with 20% FBS, 30% L929 conditioned medium as a source of 
M-CSF, 25 mM Hepes, 2 mM l-glutamine, and Pen/Strep until 
day 8. The obtained cells were a uniform population of macro-
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marker F4/80. Last, CD90.1 surface expression was used to gate the 
transduced cells.
Protein extraction and immunoblot
Whole-cell protein extraction was performed using radioimmuno-
precipitation assay extraction buffer (20 mM tris-HCl, 150 mM 
NaCl, 1% Triton X-100, 10% glycerol, and 5 mM EDTA) supple-
mented with Complete Mini protease inhibitor (Roche) and PhosSTOP 
Phosphatase Inhibitor (Roche). Proteins (15 to 50 g) were separated 
by Mini-PROTEAN TGX Stain-Free Precast Gels (4568094, Bio-Rad) 
and transferred to nitrocellulose membrane Trans-Blot Turbo Midi 
0.2-m Nitrocellulose (no. 1704159, Bio-Rad) using the Trans-Blot 
Turbo Transfer System (Bio-Rad). Nonspecific binding was blocked 
in PBS with 0.05% Tween 20 (TBST) containing 5% of bovine se-
rum albumin (BSA). The following antibodies were used: HIF-1 
(C-term) (1006421, Cayman Chemical Company), ISCU (14812-1-AP, 
Proteintech), anti–-tubulin antibody–Loading Control horseradish 
peroxidase (HRP) (ab21058, Abcam), anti-Vinculin (V9131, Sigma- 
Aldrich), and appropriate HRP-conjugated secondary antibodies 
(Santa Cruz). Signal was visualized by enhanced chemiluminescent 
reagents (ECL, Invitrogen) or West Femto by Thermo Fisher Scien-
tific according to the manufacturer’s instructions and acquired by a 
LAS 4000 charge-coupled device camera with ImageQuant software 
(GE Healthcare).
Seahorse experiment
OCR was measured by using the Seahorse XF96 plate reader. Basal 
respiration was assessed in BMDMs (7.5 × 104 cells per well) incu-
bated in a nonbuffered DMEM (D5030; Sigma-Aldrich) supple-
mented with 10 mM glucose and 2 mM glutamine. To assess 
complexes’ activity, BMDMs (7.5 × 104 cells per well) were first 
permeabilized with 1 nM Seahorse XF Plasma Membrane Permea-
bilizer (no. 102504-100; Agilent) and respiration was stimulated by 
adding 10 mM pyruvate, 5 mM malate, and 2 mM ADP. After the 
baseline scan, 100 nM rotenone was then added to inhibit complex I 
and 10 mM succinate was injected to establish complex II respira-
tion. Last, 4 M antimycin A was added to inhibit complex III and 
100 M TMPD +10 mM ascorbate was injected as a complex IV 
substrate. OCR data were then normalized according to protein 
content in each experimental well.
Radioactive metabolic assays
Radioactive metabolic analysis was performed as previously de-
scribed (71). Briefly, for glycolysis, BMDMs were incubated for 
2 hours in M199 with 10% FBS containing 0.4 Ci/ml [5-3H]-d-glucose 
(PerkinElmer). Subsequently, supernatant was transferred into glass 
vials sealed with rubber stoppers. 3H2O was captured in hanging wells 
containing a Whatman paper soaked with H2O over a period of 
48 hours at 37°C to reach saturation. The radioactivity in the paper 
was determined by liquid scintillation counting.
Metabolite analysis by LC-MS/MS
Metabolites were extracted from WT and miR-210 KO BMDMs 
(2 × 106 BMDMs per well in a six-well plate) cultured in DMEM 
(A1443001, Gibco) supplemented with 10% dialyzed FBS, 2 mM 
glutamine, and 5 mM [U-13C]-d-glucose (Cambridge Isotope Lab-
oratories). The extraction was performed using 80% methanol. 
After 5 min of incubation, cells were scraped and collected in a new 
tube. Following a centrifugation at 20,000g for 10 min at 4°C, the 
supernatant was transferred to a new vial for MS analysis. Pellet was 
used for protein quantification. For the plasma, 300 l of 80% meth-
anol was added to 100 l of sample. For analysis on condition medium, 
900 l of 80% methanol was added to 100 l of sample. After over-
night storage at −80°C, samples were centrifuged at 20,000g for 
15 min at 4°C and the supernatant was transferred to a new vial for 
MS analysis. Metabolite measurements were performed using a 
Dionex UltiMate 3000 LC System (Thermo Fisher Scientific) cou-
pled to a Q Exactive Orbitrap MS (Thermo Fisher Scientific) operated 
in negative mode. Practically, 10 l of sample was injected on an 
iHILIC-Fusion (P) column (HILICON). The gradient started with 
10% of solvent B (10 mM Na-acetate in mqH2O, pH 9.3) and 90% 
solvent A (acetonitrile) and remained at 10% B until 2 min after 
injection. Next, a linear gradient to 80% B was carried out until 
20 min. The gradient was kept at 80% B for 3 min followed by a 
decrease to 40% B. At 27 min, the gradient returned to 10% B. The 
chromatography was stopped at 35 min. The flow was kept constant 
at 200 l/min. The MS operated in full scan (range, 70 to 1050) and 
negative mode using a spray voltage of 3.2 kV, a capillary tempera-
ture of 320°C, sheath gas at 10.0, and auxiliary gas at 5.0. AGC target 
was set at 3e6 using a resolution of 70,000. Data collection was 
performed using the Xcalibur software (Thermo Fisher Scientific) 
while data analysis was performed with the software El Maven-Polly 
(Elucidata). Raw abundance values were normalized by protein 
content. The fractional contribution (FC), which is the fractional 
percentage of each of the labeled isotopolog out of the total amount 
of metabolite, was obtained by using the software El Maven-Polly 
(Elucidata), which is mostly based on the formula FC = (ni = 0 i × mi)/
(n × ni = 0 mi), where n is the number of C atoms in the metabolite, 
i denotes the isotopologs, and m indicates the abundance of an iso-
topolog. Energy charge was calculated as the following using the 
normalized raw abundancy: (ATP +  1 _2 ADP)/(ATP + ADP + AMP).
Extracellular lactate
BMDMs WT and miR-210 KO BMDMs (1 × 106 BMDMs per well 
in a six-well plate) were stimulated for 24 hours with LPS/IFN-. 
BMDMs were electroporated 48 hours before LPS/IFN- treatment 
with two siRNAs against ISCU or a control sequence. Lactate was 
measured in 2 l of cultured medium by a commercial enzymatic 
colorimetric lactate assay kit (1001330, SPINREACT) according to 
the manufacturer’s instructions.
Cytokine detection
Secretion of IL-6 was analyzed using an electrochemiluminescent 
detection assay on a SECTOR3000 (MesoScale Discovery/MSD) 
with consecutive analysis using the Discovery Workbench 4.0. 
software (MSD) or with mouse IL-6 Quantikine ELISA kit (M6000B, 
R&D Systems) according to the manufacturer’s instructions. 
TNF- and MIF levels were analyzed using a commercial mouse 
TNF- DuoSet (DY410, R&D Systems), mouse MIF DuoSet 
(DY1978, R&D Systems), and murine IL-10 DuoSet (DY217, R&D 
Systems) ELISA kit, respectively, according to the manufacturers’ 
recommendations.
RNA sequencing and analysis
RNA was extracted from BMDMs isolated from WT and miR-210 
KO mice, treated with LPS/IFN- or not treated. Per sample, an 
amount of 300 ng of total RNA was used as input. Sequencing li-
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according to the manufacturer’s protocol. Sequence libraries of 
each sample were lastly equimolarly pooled and sequenced on a 
NextSeq 500 in a 75-cycle run. The enriched GO terms of the Bio-
logical Processes tree in the DEG (LPS/IFN- and not treated, 
up-regulated and down-regulated separately) were calculated using 
the enrichGO function of clusterProfiler R package v. 3.12 on R 
Studio v. 3.6.1 and 4.0.2. The resulting GOs were also “simplified” 
using the simplify function from clusterProfiler, to remove redun-
dant GO terms. The resulting GOs were plotted using the dotplot 
function of clusterProfiler.
Proteomics
Proteins were extracted from BMDMs isolated from WT and miR-
210 KO mice, treated with LPS/IFN- or untreated. All the samples 
were run on liquid chromatography–tandem MS (LC-MS/MS) and 
searched together using the MaxQuant algorithm (version 1.6.1.0) 
with default search settings including a false discovery rate (FDR) 
set at 5% on both the peptide and protein level. Spectra were 
searched against the mouse proteins in the SWISS-PROT database 
(database release version of September 2017 containing 16,931 
mouse protein sequences) (www.uniprot.org). To reveal proteins of 
which the expression level was significantly regulated between the 
different conditions, sample groups were defined on the basis of 
treatment (untreated versus LPS/IFN-) and cell type (WT versus 
miR-210 KO), and a two-way analysis of variance (ANOVA) test 
was performed to compare the intensities of the proteins in the 
treatment group with the cell-type group. For each protein, this test 
calculated a P value (actually −log P value) for treatment, a P value 
for cell type, and a P value for the interaction between treatment 
and cell type. Overall, 2022 proteins with a P value < 0.05 in at least 
one of these three conditions were considered to be significantly 
regulated. Subsequently, using the −log10 (P value) for the interac-
tion term from the two-way ANOVA as metrics (with a positive or 
negative sign according to whether the protein abundance was 
higher or lower in the KO condition, respectively), gene set enrich-
ment analysis (73) on GO biological process gene sets was carried 
out. Significant terms were then selected on the basis of an FDR 
cutoff value of 0.05.
Human monocyte isolation
Circulating human monocytes were isolated from whole blood 
with CD14 Dynabeads (Invitrogen, catalog no. 11149D) accord-
ing to the manufacturer’s instructions. Briefly, 10  ml of whole 
blood was collected in EDTA tubes and transferred to a 15-ml 
Falcon tube containing 65 l of CD14 Dynabeads resuspended in 
isolation buffer [PBS, 0.1% BSA, and 2 mM EDTA (pH 7.4)] for a 
20-min incubation on a carousel at 4°C. After, the tube was placed 
in a magnet for 2 min and supernatant was removed. After the 
removal of the tube from the magnet, 1 ml of isolation buffer was 
used to resuspend before transfer to a new clean tube. Washes 
were performed three more times before counting. Cells were 
centrifuged 10 min at 300g. Pellets were resuspended in 350 l of lysis 
buffer (Exiqon, 1% -mercaptoethanol) and stored at −80°C. The 
clinical study was conducted according to the Declaration of Helsinki, 
and ethical committee approval was obtained from the ethical 
committee of the Antwerp University Hospital (B300201837008) 
and, for healthy volunteers, from UZ/KU Leuven (S62927). In-
formed consent was obtained from all individual participants in 
the study.
Human monocyte-derived macrophages
Briefly, as previously described (39), circulating monocytes were 
isolated from healthy blood donor buffy coats by two-step gradient 
centrifugation using Ficoll combined with a CD14 MicroBeads 
(Miltenyi Biotec Inc.) magnetic isolation step (following manufac-
turer instructions). Last, monocytes were seeded in RPMI 10% FBS, 
2 mM l-glutamine, and Pen/Strep in the presence of either recom-
binant human granulocyte M-CSF (GM-CSF) (100 ng/ml; 300-03, 
PeproTech) or recombinant human M-CSF (20 ng/ml; 300-25, 
PeproTech). Then, 50% of fresh volume with GM-CSF was added at 
day 6. Differentiated hMDMs were cultured in RPMI 1640, 10% FBS, 
2 mM l-glutamine, and Pen/Strep. For in vitro experiments with 
miR-210 modulation, 40 nM precursor miR-210 or anti–miR-210 and 
relative controls were transfected using Lipofectamine MessengerMAX 
Transfection Reagent (LMRNA003, Thermo Fisher Scientific) in 
RPMI 10% FBS, 2 mM l-glutamine, and Pen/Strep supplemented 
with GM-CSF following manufacturer instructions.
Serum samples of ICU patients with sepsis
This was a secondary analysis of the randomized controlled EPaN-
IC trial that investigated the impact of early parenteral nutrition. 
The study protocol and consent forms were approved by the insti-
tutional ethical review board (ML4190). The detailed study proto-
col and primary results have been published elsewhere (74). For this 
study, 18 nonsurviving patients with sepsis were age- and gender- 
matched to 18 surviving patients with sepsis.
Statistical analysis
Data entry and all analyses were performed in a blinded fashion. All 
statistical analyses were performed using GraphPad Prism software. 
Statistical significance was calculated by unpaired t test, one-way 
ANOVA, multiple t test using two-sided, two-sample t tests with 
Holm-Sidak correction, two-way ANOVA followed by Tukey’s or 
Sidak’s multiple comparisons test, or Mann-Whitney U test as indi-
cated in the figure legends, with P < 0.05 considered statistically sig-
nificant. Sample sizes for all experiments were chosen on the basis 
of previous experiences. Detection of mathematical outliers was 
performed using the Grubbs’ test in GraphPad. Independent exper-
iments were pooled and analyzed together whenever possible as de-
tailed in figure legends. All graphs show mean values ± SEM.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/7/19/eabf0466/DC1
View/request a protocol for this paper from Bio-protocol.
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